Alamar Biosciences, Alzheimer's Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer's Disease.

Multi-center project will profile over 40,000 samples using ultra-sensitive NULISAâ„¢ technology.

FREMONT, Calif., June 10, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, the Alzheimer's Disease Data Initiative and Gates Ventures today announced a strategic partnership with the goal to generate one of the largest proteomic datasets linked to clinical outcomes in Alzheimer's Disease (AD). This international project will profile over 40,000 plasma samples representing AD and related dementias using Alamar's ultra-sensitive NULISAâ„¢ technology, with the goal of accelerating biomarker discovery and driving new insights into the progression and treatment of AD.

"This collaboration reflects our shared commitment to transform the landscape of Alzheimer's research through data, technology, and global partnerships," said Yuling Luo, PhD, Founder, Chairman and CEO of Alamar Biosciences. "By combining our NULISA platform with Alzheimer's Disease Data Initiative's infrastructure and Gates Venture's mission-driven investment, we aim to catalyze a new era of biomarker-driven discovery and therapeutic development."

As part of the initiative, Alamar's NULISAseqâ„¢ CNS Disease Panel 120 and Inflammation Panel 250 will be implemented at research centers in the United States, Sweden, United Kingdom, and India. These panels deliver unparalleled sensitivity and specificity, enabling the accurate measurement of hundreds of brain- and immune-related proteins from just a small volume of blood or cerebrospinal fluid. A key feature of the CNS panel is its unique ability to distinguish brain-derived phosphorylated tau from total phosphorylated tau in blood—a critical advancement for the development of community-based screening programs. The resulting proteomic data will be integrated with clinical and longitudinal outcome measures and shared with the global research community by leveraging the Global Neurodegeneration Proteomics Consortium's (GNPC) secure data-sharing processes.

"Understanding the biological underpinnings of Alzheimer's Disease is essential for developing effective treatments," said Niranjan Bose, Managing Director of Health & Life Sciences at Gates Ventures and interim Executive Director of the Alzheimer's Disease Data Initiative. "This initiative will provide a rich resource to researchers worldwide and help overcome long-standing barriers in early detection and stratified interventions."

This initiative represents a major step forward in building a comprehensive, clinically annotated Alzheimer's plasma proteome atlas, with the potential to unlock new biomarkers for diagnosis, prognosis, and therapeutic response. This strategic collaboration complements the efforts of the GNPC, which has brought together top dementia researchers and datasets to collaborate and create one of the largest disease-specific proteomics datasets ever assembled. The project also emphasizes inclusivity by incorporating diverse cohorts from multiple geographic and ethnic populations.

About the Alzheimer's Disease Data Initiative
The Alzheimer's Disease Data Initiative is a coalition of leading academic, advocacy, government, industry, and philanthropy organizations that recognizes the need for dementia researchers to find easier ways to share data, analytical tools, and scientific findings. These partners are working together to accelerate progress towards new diagnostics, treatments, and cures for Alzheimer's disease and related dementias. Learn more about the Alzheimer's Disease Data Initiative at www.alzheimersdata.org.

About Alamar Biosciences, Inc.

Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGOâ„¢ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Alamar Biosciences, Alzheimer's Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer's Disease.

National competition in Shapingba District draws more than 100 teams developing robotics technologies for real-world deployment

CHONGQING, China, Sept. 18, 2026 /PRNewswire/ -- A national robotics competition held this month in Chongqing offered a look at China's efforts to move embodied artificial intelligence out of research laboratories and into commercial use.

The finals of the 11^th "Maker in China" SME Innovation and Entrepreneurship Contest for Intelligent Biomimetic Robots concluded Sept. 11 in Chongqing's Shapingba District. The three-day national competition drew more than 100 teams from across China, with projects spanning biomimetic robotics, industrial automation and AI systems designed to perceive and interact with the physical world. 

Alongside the competition, organizers arranged meetings involving companies, universities and research institutions, as well as discussions aimed at technology transfer, financing and local deployment. The event formed part of a national program intended to support innovative SMEs with specialized technologies. Its theme was "Pushing Tech Frontiers, Unleashing Creativity."

The competition comprised 13 tracks, covering work ranging from foundational research to systems approaching commercial deployment. Teams in the startup category competed in three broad areas: cutting-edge technologies, core enabling technologies and specialized applications. Their projects focused in part on the hardware, software and control systems underpinning the next generation of robots.

Teams in the enterprise category, by contrast, tested systems designed for real-world use in the electric power, healthcare and service sectors. The emphasis was on whether the technologies could perform reliably in operating environments and be scaled for broader deployment.

Many of the entries targeted technical bottlenecks that have limited the wider deployment of robotic systems. Projects included multi-robot coordination and task-scheduling systems for warehouses; assistive exoskeletons for older adults and rehabilitation patients; biomimetic robots for inspecting electric power infrastructure; miniature hummingbird-inspired flapping-wing drones; and robots capable of folding clothing autonomously. Together, the projects illustrated the range of engineering approaches Chinese developers are pursuing as they seek practical applications for embodied AI.

The competition also served as a venue for financing and business-development discussions, and several participating projects announced plans to establish operations in Shapingba. At the closing ceremony, the Shapingba District government signed letters of intent with SIASUN Robot & Automation Co., Ltd. and Chentu Technology, among other companies. ZTE also signed letters of intent with teams from Zhejiang University and Xi'an Jiaotong University.

Shapingba is seeking to establish itself as a center for embodied AI within Chongqing's broader robotics supply chain. The value of the district's robotics output rose 233% from a year earlier during the first seven months of 2026, according to local government data.

 

 

 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Xinhua Finance: Robotics Contest Highlights Chongqing District's Push Into Embodied AI